Pharmacokinetics of oral and intravenous dolasetron mesylate in patients with renal impairment

• Published in: Journal of clinical pharmacology Vol. 38; no. 9; pp. 798 - 806
• Main Authors: DIMMITT, D. C, SHAH, A. K, ARUMUGHAM, T, CRAMER, M. B, HALSTENSON, C, HORTON, M, WEIR, S. J
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Thousand Oaks, CA Sage Science 01-09-1998
• Subjects: Administration, Oral; Adult; Aged; Biological and medical sciences; Cross-Over Studies; Female; Humans; Indoles - administration & dosage; Indoles - blood; Indoles - pharmacokinetics; Indoles - urine; Kidney Diseases - metabolism; Male; Medical sciences; Middle Aged; Neuropharmacology; Neurotransmitters. Neurotransmission. Receptors; Pharmacology. Drug treatments; Quinolizines - administration & dosage; Quinolizines - blood; Quinolizines - pharmacokinetics; Quinolizines - urine; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - blood; Serotonin Antagonists - pharmacokinetics; Serotoninergic system; Kidney disease; Human; Urinary system disease; Dolasetron; Intravenous administration; Single dose; Oral administration; Controlled therapeutic trial; Metabolism; Normal; 5-HT3 Serotonine receptor; Interindividual comparison; Renal failure; Antagonist; Pharmacokinetics; Antiemetic
• ISSN: 0091-2700; 1552-4604
• DOI: 10.1002/j.1552-4604.1998.tb00012.x

In an open-label, randomized, two-way complete crossover study, the influence of renal impairment on the pharmacokinetics of dolasetron and its primary active metabolite, hydrodolasetron, were evaluated. Patients with renal impairment were stratified into three groups of 12 based on their 24-hour creatinine clearance (Cl(cr)): group 1, mild impairment (Cl(cr) between 41 and 80 mL/min); group 2, moderate impairment (Cl(cr) between 11 and 40 mL/min); and group 3, endstage renal impairment (Cl(cr) < or = 10 mL/min). Twenty-four healthy volunteers from a previous study served as the control group. Each participant received a single intravenous or oral 200-mg dose of dolasetron mesylate on separate occasions. Serial blood samples were collected up to 60 hours after dose for determination of dolasetron and hydrodolasetron, and urine samples were collected in intervals up to 72 hours for determination of dolasetron, hydrodolasetron, and the 5' and 6'-hydroxy metabolites of hydrodolasetron. Because plasma concentrations were low and sporadic, pharmacokinetic parameters of dolasetron were not calculated after oral administration. Although some significant differences in area under the concentration-time curve (AUC0-infinity), volume of distribution (Vd), systemic clearance (Cl), and elimination half-life (t1/2) of the parent drug were observed between control subjects and patients with renal impairment, there were no systematic findings related to degree of renal dysfunction. The elimination pathways of hydrodolasetron include both hepatic metabolism and renal excretion. Consistent increases in mean Cmax, AUC0-infinity, and t1/2 and decreases in renal and total apparent clearance of hydrodolasetron were seen with diminishing renal function after intravenous administration of dolasetron mesylate. No consistent changes were found after oral administration. Urinary excretion of hydrodolasetron and its metabolites decreased with decreasing renal function, but the profile of metabolites remained constant. Dolasetron was well tolerated in all three groups of patients. Based on these findings, no dosage adjustment for dolasetron is recommended in patients with renal impairment.